InventisBio Co., Limited

SHSE:688382 Stock Report

Market Cap: CN¥5.6b

InventisBio Valuation

Is 688382 undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

1/6

Valuation Score 1/6

  • Below Fair Value

  • Significantly Below Fair Value

  • Price-To-Book vs Peers

  • Price-To-Book vs Industry

  • Price-To-Book vs Fair Ratio

  • Analyst Forecast

Share Price vs Fair Value

What is the Fair Price of 688382 when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: 688382 (CN¥9.71) is trading above our estimate of fair value (CN¥7.53)

Significantly Below Fair Value: 688382 is trading above our estimate of fair value.

Key Valuation Metric

Which metric is best to use when looking at relative valuation for 688382?

Key metric: As 688382 barely has revenue we use its Price-To-Book Ratio for relative valuation analysis.

The above table shows the Price to Book ratio for 688382. This is calculated by dividing 688382's market cap by their current book value.
What is 688382's PB Ratio?
PB Ratio3.2x
BookCN¥1.73b
Market CapCN¥5.60b

Price to Book Ratio vs Peers

How does 688382's PB Ratio compare to its peers?

The above table shows the PB ratio for 688382 vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
CompanyForward PBEstimated GrowthMarket Cap
Peer Average14.1x
688062 Mabwell (Shanghai) Bioscience
4.7x58.2%CN¥8.9b
688373 Shanghai MicuRx Pharmaceutical
5.8x25.6%CN¥3.3b
688192 Dizal (Jiangsu) Pharmaceutical
43.8x58.9%CN¥18.7b
301080 AcrobiosystemsLtd
2x29.9%CN¥5.1b
688382 InventisBio
3.2x58.4%CN¥5.6b

Price-To-Book vs Peers: 688382 is good value based on its Price-To-Book Ratio (3.2x) compared to the peer average (14.1x).

Price to Book Ratio vs Industry

How does 688382's PB Ratio compare vs other companies in the CN Biotechs Industry?

0 CompaniesPrice / BookEstimated GrowthMarket Cap
No more companies available in this PB range
688382 3.2xIndustry Avg. 2.3xNo. of Companies13PB01.63.24.86.48+
0 CompaniesEstimated GrowthMarket Cap
No more companies

Price-To-Book vs Industry: 688382 is expensive based on its Price-To-Book Ratio (3.2x) compared to the CN Biotechs industry average (2.3x).

Price to Book Ratio vs Fair Ratio

What is 688382's PB Ratio compared to its Fair PB Ratio? This is the expected PB Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

688382 PB Ratio vs Fair Ratio.
Fair Ratio
Current PB Ratio3.2x
Fair PB Ration/a

Price-To-Book vs Fair Ratio: Insufficient data to calculate 688382's Price-To-Book Fair Ratio for valuation analysis.

Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

The above table shows the analyst 688382 forecast and predictions for the stock price in 12 month’s time.
DateShare PriceAverage 1Y Price TargetDispersionHighLow1Y Actual priceAnalysts
CurrentCN¥9.71
CN¥14.64
+50.8%
11.2%CN¥16.28CN¥13.00n/a2
Nov ’25CN¥10.43
CN¥14.64
+40.4%
11.2%CN¥16.28CN¥13.00n/a2
Oct ’25CN¥9.79
CN¥14.64
+49.5%
11.2%CN¥16.28CN¥13.00n/a2
Sep ’25CN¥7.35
CN¥14.64
+99.2%
11.2%CN¥16.28CN¥13.00n/a2
Aug ’25CN¥7.62
CN¥16.64
+118.4%
2.2%CN¥17.00CN¥16.28n/a2
Jul ’25CN¥7.05
CN¥16.64
+136.0%
2.2%CN¥17.00CN¥16.28n/a2
Jun ’25CN¥8.71
CN¥18.50
+112.4%
8.1%CN¥20.00CN¥17.00n/a2
May ’25CN¥9.76
CN¥22.00
+125.4%
9.1%CN¥24.00CN¥20.00n/a2
Apr ’25CN¥10.50
CN¥22.00
+109.5%
9.1%CN¥24.00CN¥20.00n/a2
Mar ’25CN¥11.45
CN¥22.00
+92.1%
9.1%CN¥24.00CN¥20.00n/a2
Feb ’25CN¥10.38
CN¥22.00
+111.9%
9.1%CN¥24.00CN¥20.00n/a2
Jan ’25CN¥15.14
CN¥22.00
+45.3%
9.1%CN¥24.00CN¥20.00n/a2
Dec ’24CN¥16.66
CN¥22.00
+32.1%
9.1%CN¥24.00CN¥20.00n/a2
Nov ’24CN¥17.46
CN¥28.50
+63.2%
29.8%CN¥37.00CN¥20.00CN¥10.432
Oct ’24CN¥13.75
CN¥27.00
+96.4%
26.9%CN¥37.00CN¥20.00CN¥9.793
Sep ’24CN¥13.49
CN¥27.00
+100.1%
26.9%CN¥37.00CN¥20.00CN¥7.353
Aug ’24CN¥14.14
CN¥27.00
+90.9%
26.9%CN¥37.00CN¥20.00CN¥7.623
Jul ’24CN¥13.69
CN¥27.00
+97.2%
26.9%CN¥37.00CN¥20.00CN¥7.053
Jun ’24CN¥18.39
CN¥30.50
+65.9%
21.3%CN¥37.00CN¥24.00CN¥8.712
May ’24CN¥21.69
CN¥30.50
+40.6%
21.3%CN¥37.00CN¥24.00CN¥9.762

Analyst Forecast: Target price is more than 20% higher than the current share price, but there are not enough analysts covering the stock to determine statistical confidence in agreement.

Discover undervalued companies

Jiangsu Kanion PharmaceuticalLtd

CN¥8.1b

Researches and develops, produces, and sells Chinese medicines.

600557

CN¥14.29

7D

-4.2%

1Y

-23.6%

China Resources Double-Crane PharmaceuticalLtd

CN¥21.4b

China Resources Double-Crane Pharmaceutical Co.,Ltd.

600062

CN¥20.80

7D

-3.9%

1Y

12.1%

Hunan Jiudian Pharmaceutical

CN¥11.5b

Researches, develops, produces, and sells pharmaceutical products in China and internationally.

300705

CN¥23.19

7D

-2.6%

1Y

13.6%